Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Unveils Adverse Event Reporting Rules For Combination Products

This article was originally published in The Gray Sheet

Executive Summary

FDA says its proposed adverse event reporting requirements for combination products will help manufacturers navigate the intricate array of reporting requirements for deaths and injuries

You may also be interested in...



2016 Will Be A Big Year For Combo Product Reform, FDA Says

Having earlier signaled its plan to propose a new statutory pathway for combination products by the end of 2016, the agency is now working on a bevy of process changes, guidance documents and rules to enhance premarket and postmarket regulation of combination products in the years ahead.

2016 Will Be A Big Year For Combo Product Reform, FDA Says

The agency has already signaled its plan to propose a new statutory pathway for combination products by the end of next year. In the meantime, it's working on a bevy of process changes, guidance documents and rules to enhance premarket and postmarket regulation of combination products in the years ahead. Office of Combination Products officials John Weiner and Thinh Nguyen weigh in.

UDI Final Rule Listed For July Release In HHS Regulatory Agenda

The UDI final rule is among 11 device-focused proposed and final regulations included in the HHS unified agenda of regulations planned through early 2014, and it is likely the most closely watched of the group by industry.

Related Content

Topics

UsernamePublicRestriction

Register

MT027994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel